Display options
Cite
Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when?. World J Gastrointest Pharmacol Ther. 2016;7(1):33-40doi: 10.4292/wjgpt.v7.i1.33.
Attar, B. M., & Van Thiel, D. H. (2016). Hepatitis C virus: A time for decisions. Who should be treated and when?. World journal of gastrointestinal pharmacology and therapeutics, 7(1), 33-40. https://doi.org/10.4292/wjgpt.v7.i1.33
Attar, Bashar M, and Van Thiel, David H. "Hepatitis C virus: A time for decisions. Who should be treated and when?." World journal of gastrointestinal pharmacology and therapeutics vol. 7,1 (2016): 33-40. doi: https://doi.org/10.4292/wjgpt.v7.i1.33
Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when?. World J Gastrointest Pharmacol Ther. 2016 Feb 06;7(1):33-40. doi: 10.4292/wjgpt.v7.i1.33. PMID: 26855810; PMCID: PMC4734952.
Copy Download .nbib Format: NLM
Share it on

World J Gastrointest Pharmacol Ther. 2016 Feb 06;7(1):33-40. doi: 10.4292/wjgpt.v7.i1.33.

Hepatitis C virus: A time for decisions. Who should be treated and when?.

World journal of gastrointestinal pharmacology and therapeutics

Bashar M Attar, David H Van Thiel

Affiliations

  1. Bashar M Attar, Cook County Health and Hospitals System, Rush University Medical Center, Chicago, IL 60612, United States.

PMID: 26855810 PMCID: PMC4734952 DOI: 10.4292/wjgpt.v7.i1.33

Abstract

Cirrhosis is the most important risk factor for hepatocellular carcinoma (HCC) regardless of the etiology of cirrhosis. Compared to individuals who are anti-hepatitis C virus (HCV) seronegative, anti-HCV seropositive individuals have a greater mortality from both hepatic as well as nonhepatic disease processes. The aim of this paper is do describe the burden of HCV infection and consider treatment strategies to reduce HCV-related morbidity and mortality. The newly developed direct acting antiviral (DAA) therapies are associated with greater rates of drug compliance, fewer adverse effects, and appear not to be limited by the presence of a variety of factors that adversely affect the outcome of interferon-based therapies. Because of the cost of the current DAA, their use has been severely rationed by insurers as well as state and federal agencies to those with advanced fibrotic liver disease (Metavir fibrosis stage F3-F4). The rationale for such rationing is that many of those recognized as having the disease progress slowly over many years and will not develop advanced liver disease manifested as chronic hepatitis C, cirrhosis, and experience any of the multiple complications of liver disease to include HCC. This mitigation has a short sided view of the cost of treatment of hepatitis C related disease processes and ignores the long-term expenses of hepatitis C treatment consisting of the cost of treatment of hepatitis C, the management of cirrhosis with or without decompensation as well as the cost of treatment of HCC and liver transplantation. We believe that treatment should include all HCV infected patients including those with stage F0-F2 fibrosis with or without evidence of coexisting liver disease. Specifically, interferon (IFN)-free regimens with the current effective DAAs without liver staging requirements and including those without evidence of hepatic diseases but having recognized extrahepatic manifestations of HCV infection is projected to be the most cost-effective approach for treating HCV in all of its varied presentations. Early rather than later therapy of HCV infected individuals would be even more efficacious than waiting particularly if it includes all cases from F0-F4 hepatic disease. Timely therapy will reduce the number of individuals developing advanced liver disease, reduce the cost of treating these cases and more importantly, reduce the lifetime cost of treatment of those with any form of HCV related disease as well as HCV associated all - cause mortality. Importantly, HCV treatment regimens without any restrictions would result in a substantial reduction in health care expenditure and simultaneously reduce the number of infected individuals who are infecting others.

Keywords: Cirrhosis of the liver; Direct acting antivirals; Hepatitis C virus; Timing of treatment

References

  1. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1017-29 - PubMed
  2. JAMA. 2012 Dec 26;308(24):2584-93 - PubMed
  3. Can J Gastroenterol Hepatol. 2014 May;28(5):243-50 - PubMed
  4. JAMA. 2014 Aug 13;312(6):631-40 - PubMed
  5. Acta Gastroenterol Belg. 2015 Jun;78(2):228-32 - PubMed
  6. Cancer Epidemiol. 2010 Dec;34(6):709-12 - PubMed
  7. Liver Int. 2013 Feb;33 Suppl 1:105-10 - PubMed
  8. JAMA. 2014 Jun 11;311(22):2262-3 - PubMed
  9. J Viral Hepat. 2013 Apr;20(4):263-72 - PubMed
  10. Gastroenterology. 2014 May;146(5):1176-92 - PubMed
  11. World J Gastroenterol. 2014 Aug 28;20(32):11033-53 - PubMed
  12. J Infect Dis. 2006 Jul 1;194(1):53-60 - PubMed
  13. Clin Infect Dis. 2015 Sep 1;61(5):730-40 - PubMed
  14. J Med Virol. 2010 Dec;82(12):2032-7 - PubMed
  15. J Viral Hepat. 2014 Aug;21(8):568-77 - PubMed
  16. Hepatology. 2006 Jul;44(1):15-22 - PubMed
  17. Hepatology. 2013 Jun;57(6):2164-70 - PubMed
  18. Clin Med Insights Oncol. 2014 May 19;8:71-6 - PubMed
  19. World J Gastroenterol. 2014 Jun 14;20(22):6707-15 - PubMed
  20. J Viral Hepat. 2013 Dec;20(12):847-57 - PubMed
  21. Gastroenterology. 2014 May;146(5):1145-50.e1-4 - PubMed
  22. J Virol. 2005 May;79(10):6349-57 - PubMed
  23. Liver Int. 2014 Feb;34 Suppl 1:38-45 - PubMed
  24. Gut. 2005 May;54(5):682-5 - PubMed
  25. Gut. 2015 Feb;64(2):322-31 - PubMed
  26. Dig Liver Dis. 2007 Sep;39 Suppl 1:S38-45 - PubMed
  27. J Hepatol. 2001 May;34(5):730-9 - PubMed
  28. Hepatology. 2015 May;61(5):1471-8 - PubMed
  29. Curr Opin Gastroenterol. 2014 May;30(3):217-22 - PubMed
  30. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10 - PubMed
  31. Clin Pharmacol. 2014 Jan 08;6:1-17 - PubMed
  32. AIDS Patient Care STDS. 2014 May;28(5):228-39 - PubMed
  33. J Hepatol. 2014 Sep;61(3):482-91 - PubMed
  34. J Viral Hepat. 2013 Nov;20(11):745-60 - PubMed
  35. PLoS One. 2013 Apr 30;8(4):e62319 - PubMed
  36. World J Gastroenterol. 2014 Jun 14;20(22):6701-6 - PubMed
  37. Liver Int. 2014 Jul;34(6):e80-8 - PubMed
  38. J Viral Hepat. 2014 Mar;21(3):208-15 - PubMed
  39. Hepatology. 2014 Jul;60(1):37-45 - PubMed
  40. J Infect Dis. 2012 Aug 15;206(4):469-77 - PubMed
  41. J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9 - PubMed
  42. Liver Int. 2013 Feb;33 Suppl 1:46-55 - PubMed
  43. World J Gastroenterol. 2012 Jun 21;18(23):2887-94 - PubMed
  44. J Virol. 2006 Nov;80(22):10972-9 - PubMed
  45. Liver Int. 2014 Feb;34 Suppl 1:79-84 - PubMed
  46. Clin Liver Dis. 2013 Feb;17(1):1-11 - PubMed
  47. BMJ. 2014 Jul 07;348:g3308 - PubMed
  48. Ann Intern Med. 2013 Jan 15;158(2):114-23 - PubMed
  49. Hepatology. 2015 May;61(5):1495-502 - PubMed
  50. Am J Gastroenterol. 2014 May;109(5):628-35; quiz 636 - PubMed
  51. Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62 - PubMed
  52. J Med Econ. 2014 Dec;17(12):862-71 - PubMed
  53. Acta Gastroenterol Belg. 2014 Jun;77(2):285-90 - PubMed
  54. Ann Intern Med. 2014 Aug 5;161(3):170-80 - PubMed
  55. J Hepatol. 2006;44(1 Suppl):S19-24 - PubMed

Publication Types